Edition:
United States

Eisai Co Ltd (4523.T)

4523.T on Tokyo Stock Exchange

5,612JPY
18 Aug 2017
Change (% chg)

¥-81 (-1.42%)
Prev Close
¥5,693
Open
¥5,673
Day's High
¥5,674
Day's Low
¥5,605
Volume
642,000
Avg. Vol
742,922
52-wk High
¥7,280
52-wk Low
¥5,581

Latest Key Developments (Source: Significant Developments)

Eisai amends consolidated full-year outlook for FY 2016
Wednesday, 30 Mar 2016 02:00am EDT 

Eisai Co Ltd:Says the company lowered the consolidated full-year outlook for revenue to 547,000 mln yen from 556,500 mln yen for the fiscal year ending March 31, 2016.Confirms the operating profit forecast at 51,000 mln yen.Confirms the ordinary profit forecast at 49,000 mln yen.Net profit forecast increased to 50,000 mln yen from 37,000 mln yen.Earnings per share increased to 174.28 yen from 129 yen.Says net profit outlook raised due to the gain on sale of unit AkaRx, Inc.  Full Article

Eisai Co Ltd - Notice Regarding Discontinuation of Sales and Voluntary Recall of Egg White Lysozyme Preparation Neuzym - JCN
Wednesday, 16 Mar 2016 07:08pm EDT 

Eisai Co Ltd:Eisai Co Ltd's subsidiary Sannova Co., Ltd. has been informed the results of deliberation of the Committee on Reevaluation of the Pharmaceutical Affairs and Food Sanitation Council's regarding the egg white lysozyme preparation Neuzym which had been submitted for reevaluation - JCN.The Committee's opinion was that "the medical usefulness of lysozyme in the present medical environment is thought to have decreased, and its usefulness cannot be confirmed at this point in time." As such, sales of the product have been discontinued, and a voluntary recall is being conducted as of today.Regarding safety of the products, no unusual issues have been observed since launch, and there were no issues observed in these post-marketing clinical studies as well.In the studies on bronchitis, bronchial asthma and bronchiectasis, the efficacy of lysozyme as an add-on to standard treatment in patients with chronic obstructive pulmonary disease (COPD) was considered.Based on the results of these studies, the companies submitted an application for reevaluation of efficacy on May 29, 2015.Regarding chronic sinusitis, an application for a partial label change to remove the indication of chronic sinusitis for Neuzym was submitted on May 29, 2015, and was approved (indication removed) on December 11, 2015.  Full Article

Eisai raises consolidated full-year outlook for FY 2016
Monday, 1 Feb 2016 10:30pm EST 

Eisai Co Ltd:Says the company reaffirmed the consolidated full-year outlook for revenue at 556,500 mln yen for the fiscal year ending March 31, 2016.Operating profit forecast increased to 51,000 mln yen from 46,000 mln yen.Ordinary profit forecast increased to 49,000 mln yen from 42,800 mln yen.Net profit forecast increased to 37,000 mln yen from 27,000 mln yen.Earnings per share increased to 129 yen from 93.83 yen.Comments the increased sales in core business and lower tax expenses are the main reasons for the forecast.  Full Article

Eisai to sell subsidiary to Alfresa Holdings
Friday, 18 Dec 2015 03:10am EST 

Eisai Co Ltd:Entered into a business acquisition agreement with Alfresa Holdings Corporation, concerning the splitting off of Eisai's consolidated pharmaceutical manufacturing and marketing subsidiary Sannova Co., Ltd. (Shareholding ratio: 79.5 pct) via an absorption-type split.Says succession by a newly established company and the subsequent transfer of all shares issued in this new company to Alfresa Holdings.The effective date of this absorption-type split is scheduled to be March 31, 2016, and the date of the share transfer is scheduled to be April 1, 2016.  Full Article

Eisai to sell shares of wholly owned subsidiary to Mitsubishi-Kagaku Foods Corporation
Thursday, 26 Nov 2015 01:30am EST 

Eisai Co Ltd:To sell 2,001 shares of its wholly owned subsidiary, which has been engaged in development, sales and export of medical and cosmetic material, food additives and healthy food material in Tokyo, Japan, to Mitsubishi-Kagaku Foods Corporation.Effective date Feb. 1, 2016.After the transaction, the company will hold no stake in the subsidiary, down from 100 pct.  Full Article

Eisai to sell subsidiary to Sekisui Chemical
Friday, 20 Nov 2015 01:30am EST 

Eisai Co Ltd:To sell 17,979,195 shares (100 pct stake) in its wholly owned Tokyo-based subsidiary EIDIA Co.,Ltd to Sekisui Chemical Co Ltd, at price of 22,450 mln yen in total, on Dec. 28.To cut stake in the subsidiary to 0 pct from 100 pct.  Full Article

Eisai announces business integration with subsidiary of Ajinomoto
Thursday, 15 Oct 2015 02:00am EDT 

Eisai Co Ltd:To tranfer gastroenterology diseases related business to a wholly owned subsidiary of Ajinomoto, effective April 1, 2016.Subsidiary of Ajinomoto to issue 6,000 shares to the company.The subsidiary of Ajinomoto to change name to EA Pharma Co Ltd.To hold 60 pct stake in EA Pharma.  Full Article

Eisai amends consolidated mid-year outlook for FY 2016
Tuesday, 29 Sep 2015 07:30pm EDT 

Eisai Co Ltd:Says the company lowered the consolidated mid-year outlook for revenue to 275,000 mln yen from 277,500 mln yen for the fiscal year ending March 31, 2016.Operating profit forecast increased to 14,500 mln yen from 10,000 mln yen.Ordinary profit forecast increased to 14,000 mln yen from 8,400 mln yen.Net profit forecast increased to 9,000 mln yen from 6,000 mln yen.Earnings per share increased to 30.98 yen from 20.66 yen.Says profit outlook raised due to the cost reduction.  Full Article

Eisai Co Ltd announces FDA acceptance of NDA
Monday, 14 Sep 2015 08:30am EDT 

Eisai Co Ltd:Announces FDA acceptance of NDA for review of fycompa oral suspension for adjunctive therapy in the treatment of partial-onset seizures and primary generalized tonic-clonic seizures in patients with epilepsy age 12 and older.  Full Article

Eisai Co Ltd and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant
Monday, 31 Aug 2015 07:30am EDT 

Eisai Co Ltd:Says Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered into a worldwide collaboration agreement.Says that they have entered into a worldwide collaboration agreement for the development and commercialization of Eisai's clinical candidate lemborexant, a dual orexin receptor antagonist entering Phase III clinical development for the treatment of insomnia.  Full Article

BRIEF-FDA approves Eisai's Fycompa for use as monotherapy for the treatment of partial-onset seizures

* FDA approves Eisai's Fycompa® (perampanel) for use as monotherapy for the treatment of partial-onset seizures